Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

10x Genomics Yönetim

Yönetim kriter kontrolleri 4/4

10x Genomics' CEO'su Serge Saxonov, Jul2012 tarihinde atandı, in görev süresi 12.25 yıldır. in toplam yıllık tazminatı $ 8.29M olup, şirket hissesi ve opsiyonları dahil olmak üzere 6.6% maaş ve 93.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 3.34% ine doğrudan sahiptir ve bu hisseler $ 90.89M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 7.3 yıl ve 5.5 yıldır.

Anahtar bilgiler

Serge Saxonov

İcra Kurulu Başkanı

US$8.3m

Toplam tazminat

CEO maaş yüzdesi6.6%
CEO görev süresi12.3yrs
CEO sahipliği3.3%
Yönetim ortalama görev süresi5.5yrs
Yönetim Kurulu ortalama görev süresi5.5yrs

Son yönetim güncellemeleri

Recent updates

10x Genomics Is Still A Long Way From Profitability

Oct 03

We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Sep 09
We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Investors Still Aren't Entirely Convinced By 10x Genomics, Inc.'s (NASDAQ:TXG) Revenues Despite 30% Price Jump

Aug 10
Investors Still Aren't Entirely Convinced By 10x Genomics, Inc.'s (NASDAQ:TXG) Revenues Despite 30% Price Jump

10x Genomics Stock Slips As Illumina Snaps Up Competitor - Tough Times Ahead

Jul 10

10x Genomics: Sticking To The Plan To Avoid The Falling The Knife

Jun 21

Take Care Before Jumping Onto 10x Genomics, Inc. (NASDAQ:TXG) Even Though It's 26% Cheaper

Jun 14
Take Care Before Jumping Onto 10x Genomics, Inc. (NASDAQ:TXG) Even Though It's 26% Cheaper

10x Genomics (NASDAQ:TXG) Is In A Strong Position To Grow Its Business

May 21
10x Genomics (NASDAQ:TXG) Is In A Strong Position To Grow Its Business

Why We're Not Concerned About 10x Genomics, Inc.'s (NASDAQ:TXG) Share Price

Apr 15
Why We're Not Concerned About 10x Genomics, Inc.'s (NASDAQ:TXG) Share Price

Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

Feb 05
Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

10x Genomics: Sales Are Growing At A Rapid Rate, But So Are Expenses

Jan 20

Revenues Tell The Story For 10x Genomics, Inc. (NASDAQ:TXG) As Its Stock Soars 31%

Dec 22
Revenues Tell The Story For 10x Genomics, Inc. (NASDAQ:TXG) As Its Stock Soars 31%

We're Hopeful That 10x Genomics (NASDAQ:TXG) Will Use Its Cash Wisely

Nov 03
We're Hopeful That 10x Genomics (NASDAQ:TXG) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

Aug 04
Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

Why Investors Shouldn't Be Surprised By 10x Genomics, Inc.'s (NASDAQ:TXG) P/S

Jun 04
Why Investors Shouldn't Be Surprised By 10x Genomics, Inc.'s (NASDAQ:TXG) P/S

At US$52.43, Is 10x Genomics, Inc. (NASDAQ:TXG) Worth Looking At Closely?

Apr 29
At US$52.43, Is 10x Genomics, Inc. (NASDAQ:TXG) Worth Looking At Closely?

10x Genomics, Inc. (NASDAQ:TXG) Shares Could Be 28% Below Their Intrinsic Value Estimate

Mar 24
10x Genomics, Inc. (NASDAQ:TXG) Shares Could Be 28% Below Their Intrinsic Value Estimate

We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Feb 02
We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Is Now The Time To Look At Buying 10x Genomics, Inc. (NASDAQ:TXG)?

Jan 12
Is Now The Time To Look At Buying 10x Genomics, Inc. (NASDAQ:TXG)?

An Intrinsic Calculation For 10x Genomics, Inc. (NASDAQ:TXG) Suggests It's 39% Undervalued

Dec 22
An Intrinsic Calculation For 10x Genomics, Inc. (NASDAQ:TXG) Suggests It's 39% Undervalued

10x Genomics: No Signs Of A Growth Turnaround, Heavy Bearish Momentum

Oct 12

CEO Tazminat Analizi

Serge Saxonov'un ücretlendirmesi 10x Genomics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-US$240m

Mar 31 2024n/an/a

-US$264m

Dec 31 2023US$8mUS$545k

-US$255m

Sep 30 2023n/an/a

-US$223m

Jun 30 2023n/an/a

-US$172m

Mar 31 2023n/an/a

-US$174m

Dec 31 2022US$19mUS$504k

-US$166m

Sep 30 2022n/an/a

-US$167m

Jun 30 2022n/an/a

-US$142m

Mar 31 2022n/an/a

-US$89m

Dec 31 2021US$12mUS$430k

-US$58m

Sep 30 2021n/an/a

-US$455m

Jun 30 2021n/an/a

-US$504m

Mar 31 2021n/an/a

-US$533m

Dec 31 2020US$11mUS$400k

-US$543m

Sep 30 2020n/an/a

-US$134m

Jun 30 2020n/an/a

-US$78m

Mar 31 2020n/an/a

-US$49m

Dec 31 2019US$2mUS$394k

-US$31m

Sep 30 2019n/an/a

-US$100m

Jun 30 2019n/an/a

-US$105m

Mar 31 2019n/an/a

-US$105m

Dec 31 2018US$1mUS$366k

-US$112m

Tazminat ve Piyasa: Serge 'ın toplam tazminatı ($USD 8.29M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 6.79M ).

Tazminat ve Kazançlar: Serge 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.


CEO

Serge Saxonov (47 yo)

12.3yrs

Görev süresi

US$8,286,050

Tazminat

Dr. Serge Saxonov, Ph D, Co-Founded 10X Genomics, Inc. and has been its Chief Executive Officer and Director since July 2012. Prior to 10x Genomics, Dr. Saxonov was Vice President of Applications at Quanta...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Serge Saxonov
Co-Founder12.3yrsUS$8.29m3.34%
$ 78.9m
Benjamin Hindson
Co-Founder12.3yrsUS$4.43m2.69%
$ 63.5m
Eric Whitaker
Chief Legal Officer7.3yrsUS$3.88m0.12%
$ 2.8m
Jim Goodrich
Chief of Global Operationsless than a yearVeri yokVeri yok
Michael Schnall-Levin
Founding Scientist & CTO2.8yrsVeri yokVeri yok
Cassie Corneau
Manager of Investor Relations and Strategic Financeno dataVeri yokVeri yok
Rebecca Port
Chief People Officer3.8yrsVeri yokVeri yok
Jens Durruthy
Associate Director of Product Managementno dataVeri yokVeri yok

5.5yrs

Ortalama Görev Süresi

49yo

Ortalama Yaş

Deneyimli Yönetim: TXG 'un yönetim ekibi deneyimli ve deneyimlidir ( 7.3 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Serge Saxonov
Co-Founder12.3yrsUS$8.29m3.34%
$ 78.9m
Benjamin Hindson
Co-Founder12.3yrsUS$4.43m2.69%
$ 63.5m
Kimberly Popovits
Independent Director4.6yrsUS$338.71k0.0038%
$ 90.5k
John Stuelpnagel
Independent Chairman11.2yrsUS$403.59k2.03%
$ 47.9m
Shehnaaz Suliman
Independent Director5.2yrsUS$336.39k0.0038%
$ 90.5k
Alan Mateo
Directorless than a yearVeri yokVeri yok
Mathai Mammen
Independent Director7.2yrsUS$331.39k0.14%
$ 3.4m
Sridhar Kosaraju
Independent Director5.5yrsUS$346.39k0.029%
$ 695.1k
Sarah Polonius-Teichmann
Directorless than a yearVeri yokVeri yok

5.5yrs

Ortalama Görev Süresi

54.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: TXG 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.5 yıldır).